INDV (Indivior Pharmaceuticals) Total Liabilities: $1,341 Mil (As of Mar. 2026)

What is Indivior Pharmaceuticals Total Liabilities?

Indivior Pharmaceuticals INDV +1.31% 69 Total Liabilities is $1,341 Mil as of Mar. 2026. GuruFocus rates INDV with a GF Score™ of 69/100 and a GF Value™ of $22.98 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Indivior Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $1,341 Mil.

Indivior Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 ($1,623.00 Mil) to Dec. 2025 ($1,300.00 Mil) but then increased from Dec. 2025 ($1,300.00 Mil) to Mar. 2026 ($1,341.00 Mil).

Indivior Pharmaceuticals's annual Total Liabilities declined from Dec. 2023 ($1,952.00 Mil) to Dec. 2024 ($1,653.00 Mil) and declined from Dec. 2024 ($1,653.00 Mil) to Dec. 2025 ($1,300.00 Mil).

Indivior Pharmaceuticals Total Liabilities Related Terms

Indivior Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Indivior Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indivior Pharmaceuticals Total Liabilities Chart

Indivior Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

1,629.00

1,718.00

1,952.00

1,653.00

1,300.00

Indivior Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Liabilities	Get a 7-Day Free Trial															1,661.00	1,710.00	1,623.00	1,300.00	1,341.00

69GF Score

Indivior Pharmaceuticals Inc INDV

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Indivior Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Indivior Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	914	+	(312	+	74
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,300

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	1201	-	-99
	=	1,300

Indivior Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	779	+	(500	+	62
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,341

Total Liabilities	=	Total Assets (Q: Mar. 2026 )	-	Total Equity (Q: Mar. 2026 )
	=	1197	-	-144
	=	1,341

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of $1,341 Mil mean?

Indivior Pharmaceuticals (INDV) has a Total Liabilities of $1,341 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Indivior Pharmaceuticals and its competitors.

Is Indivior Pharmaceuticals' Total Liabilities too high?

Indivior Pharmaceuticals' current Total Liabilities is $1,341 Mil. Overall, Indivior Pharmaceuticals has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Indivior Pharmaceuticals' Total Liabilities compare to AMRX and KNSA?

Indivior Pharmaceuticals' Total Liabilities of $1,341 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Drug Manufacturers company?

A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Indivior Pharmaceuticals and its competitors. Indivior Pharmaceuticals's current Total Liabilities is $1,341 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Indivior Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Indivior Pharmaceuticals (INDV) is currently considered Significantly Overvalued. The stock's GF Value™ is $22.98, compared to a current price of $41.82 — trading 82% above its estimated fair value. The current Total Liabilities is $1,341 Mil. Indivior Pharmaceuticals' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Indivior Pharmaceuticals (INDV), the current Total Liabilities is $1,341 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Indivior Pharmaceuticals (INDV) Overvalued in 2026?

Based on GuruFocus' analysis, Indivior Pharmaceuticals stock appears to be overvalued. The current stock price of $41.82 is trading 82% above its estimated GF Value™ of $22.98. GuruFocus considers Indivior Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INDV:

Total Liabilities: $1,341 Mil
GF Value™: $22.98 vs. price of $41.82 (82% above fair value)
GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the INDV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Indivior Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies AMRX KNSA LQDA SUPN HIMS BCRX PBH LNTH ANIP AMLX XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges E7P:Germany

Address 10710 Midlothian Turnpike, Suite 125, North Chesterfield, Richmond, VA, USA, 23235

Website https://www.indivior.com

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

69GF Score

Get the complete analysis for INDV

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.82

Price

$22.98

GF Value

View INDV Analysis

See Total Liabilities data for all stocks →